DNA double helix edited by CRISPR molecule in futuristic lab.

Breakthroughs in Biotech: CRISPR, Genomics, and Corporate News

Nico Varela in Tech & Innovation September 2025 • 3 min read.

"Stay ahead of the curve with the latest advancements in genetic engineering, genomic services, and biotech industry deals."

The biotechnology sector is continually evolving, marked by groundbreaking research, strategic acquisitions, and innovative collaborations. Keeping abreast of these developments is crucial for stakeholders ranging from researchers and healthcare professionals to investors and policymakers.

This article delves into recent pivotal events in the biotech arena, highlighting advancements in CRISPR technology, the acquisition of genomic services businesses, and the launch of major joint ventures. Each of these developments signifies important shifts and opportunities within the industry.

Our focus will be on providing an accessible yet comprehensive overview, ensuring that readers—whether seasoned experts or curious newcomers—can grasp the significance and potential impact of these innovations.

Genewiz Acquires Beckman Coulter's Genomic Services: A Strategic Expansion

DNA double helix edited by CRISPR molecule in futuristic lab.

Genewiz's acquisition of Beckman Coulter's Genomic Services (GS) business represents a significant step in expanding its service offerings and market reach. This strategic move allows Genewiz to integrate Beckman Coulter's sequencing services, known for their bioinformatics solutions, into its existing portfolio.

The acquisition is particularly beneficial as it enhances Genewiz's ability to serve a broader range of clients, including healthcare businesses, academic institutions, and government agencies worldwide. By incorporating Beckman Coulter's GS business, Genewiz is poised to offer more comprehensive solutions in the genomic services sector.

Here’s a breakdown of what this acquisition means for Genewiz and the industry:

Enhanced Service Portfolio: Genewiz adds Sanger sequencing and bioinformatics solutions to its existing services.
Expanded Market Reach: The acquisition extends Genewiz's services to more healthcare businesses, academic institutions, and government agencies.
Comprehensive Genomic Solutions: Integration of services allows Genewiz to offer a more complete suite of genomic solutions.

This acquisition not only strengthens Genewiz’s market position but also underscores the increasing demand for comprehensive genomic services. As the biotech landscape evolves, such strategic consolidations will likely become more common, driving innovation and efficiency in the industry.

Bayer and CRISPR Therapeutics Launch $335M+ Joint Venture: A New Era in Gene Editing

The collaboration between Bayer and CRISPR Therapeutics marks a significant milestone in the application of CRISPR-Cas9 technology. With a $335 million investment, this joint venture aims to discover, develop, and commercialize new therapies for blood disorders, blindness, and congenital heart disease, areas with significant unmet medical needs.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

Everything You Need To Know

What is CRISPR technology, and why is it such a big deal in biotechnology?

CRISPR technology, specifically CRISPR-Cas9, is a groundbreaking gene-editing tool that allows scientists to make precise alterations to DNA. This is significant because it opens up new possibilities for treating and potentially curing genetic diseases. Bayer and CRISPR Therapeutics have launched a joint venture to leverage CRISPR-Cas9 for developing therapies for conditions like blood disorders, blindness, and congenital heart disease. The implications of CRISPR extend beyond these specific areas, offering potential applications in various fields, including agriculture and other human diseases.

What are genomic services, and why are they important in the context of healthcare and research?

Genomic services refer to a range of services centered around the study and application of an organism's complete set of DNA, known as its genome. These services include DNA sequencing, bioinformatics, and genetic analysis. Genomic services are critical because they enable researchers and healthcare providers to understand the genetic basis of diseases, develop personalized treatments, and advance our understanding of biology. Genewiz's acquisition of Beckman Coulter's Genomic Services business is a strategic move to expand service offerings, enhance market reach, and offer more comprehensive solutions in the genomic services sector.

What is a joint venture, and why is the one between Bayer and CRISPR Therapeutics so noteworthy?

A joint venture is a business arrangement in which two or more parties agree to pool their resources for the purpose of accomplishing a specific task. The Bayer and CRISPR Therapeutics joint venture, backed by a $335 million investment, exemplifies this by combining Bayer's expertise in drug development with CRISPR Therapeutics' pioneering CRISPR-Cas9 technology. This allows them to jointly discover, develop, and commercialize new therapies. The significance of this venture lies in its potential to accelerate the development of treatments for challenging diseases, showcasing how collaborative efforts can drive innovation in the biotech industry.

Why is the acquisition of Beckman Coulter's Genomic Services by Genewiz considered a strategic expansion?

The acquisition of Beckman Coulter's Genomic Services by Genewiz is important for several reasons. It allows Genewiz to enhance its service portfolio by adding Sanger sequencing and bioinformatics solutions, expand its market reach to more healthcare businesses, academic institutions, and government agencies, and offer more comprehensive genomic solutions. This acquisition strengthens Genewiz's market position and reflects the increasing demand for comprehensive genomic services. Strategic consolidations like these are likely to become more common, driving innovation and efficiency in the industry.

What are corporate ventures in the biotech industry, and why are they significant?

Corporate ventures in biotechnology refer to strategic activities companies undertake to innovate, grow, and gain a competitive edge. These can include mergers, acquisitions, joint ventures, and significant investments in research and development. These ventures are significant because they drive innovation, expand market reach, and address unmet medical needs. Examples include Genewiz's acquisition of Beckman Coulter's Genomic Services, and the joint venture between Bayer and CRISPR Therapeutics. Corporate ventures have broad implications for the development of new technologies, therapies, and healthcare solutions.